维普中文期刊产品整合服务
37篇 您的检索式:作者名="HC So"
    题名 作者 年代 出处 被引量
1Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy显示文摘Hepatitis due to hepatitis B virus(HBV) reactivation can be severe and potentially fatal, but is preventable. HBV reactivation is most commonly reported in patients receiving cancer chemotherapy, especially rituximabcontaining therapy for hematological malignancies and those receiving stem cell transplantation. All patients with hematological malignancies receiving anticancer therapy should be screened for active or resolved HBV infection by blood tests for hepatitis B surface antigen(HBs Ag) and antibody to hepatitis B core antigen(antiHBc). Patients found to be positive for HBs Ag should be given prophylactic antiviral therapy to prevent HBV reactivation. For patients with resolved HBV infection, no standard strategy has yet been established to prevent HBV reactivation. There are usually two options. One is pre-emptive therapy guided by serial HBV DNA monitoring, whereby antiviral therapy is given as soon as HBV DNA becomes detectable. However, there is little evidence regarding the optimal interval and period of monitoring. An alternative approach is prophylactic antiviral therapy, especially for patients receiving highrisk therapy such as rituximab, newer generation of anti-CD20 monoclonal antibody, obinutuzumab or hematopoietic stem cell transplantation. This strategy may effectively prevent HBV reactivation and avoid the inconvenience of repeated HBV DNA monitoring. Entecavir or tenofovir are preferred over lamivudine as prophylactic therapy. Although there is no well-defined guideline on the optimal duration of prophylactic therapy, there is growing evidence to recommend continuing prophylactic antiviral therapy for at least 12 mo after cessation of chemotherapy, and even longer for those who receive rituximab or who had high serum HBV DNA levels before the start of immunosuppressive therapy. Many novel agents have recently become available for the treatment of hematological malignancies, and these agents may be associated with HBV reactivation. Although there is currently limited evidence to guide the optimal preventive measures, we recommend antiviral prophylaxis in HBs Ag-positive patients receiving novel treatments, especially the Bruton tyrosine kinase inhibitors and the phosphatidylinositol 3-kinase inhibitors, which are B-cell receptor signaling modulators and reduce proliferation of malignant B-cells. Further studies are needed to clarify the risk of HBV reactivation with these agents and the best prophylactic strategy in the era of targeted therapy for hematological malignancies.Man Fai Law Rita Ho Carmen KM Cheung Lydia HP Tam Karen Ma Kent CY So Bonaventure Ip Jacqueline So Jennifer Lai Joyce Ng Tommy HC Tam 2016World Journal of Gastroenterology2016,22,28:10
2Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme 显示文摘Looker HC Nyangoma SO Cromie DT 2013Diabe- tologia2013,56,8:1
3New computerized indices forquantitative evaluation of depression and asymmetry in patientswith chest wall deformities显示文摘Kim HC Choi H Jin SO 2013Artif Organs2013,37,8:1
4Low intensity ultrasound as a sup-porter of cartilage regeneration and its engineering显示文摘BYoung-Hyun M Byung HC So RP 2007Biotechnol Bio-process Eng2007,11,1:1
5Subspace-based algorithm for parameter estimation of polynomial phase signals 显示文摘Y Wu HC So H Liu 2008IEEE Tram Signal Process2008,56,10:1
6Age-dependent resistance to Cryptosporidium muris (strain MCR) infection in golden hamsters and mice显示文摘Rhee JK So WS Kim HC 1999The Korean Journal of Parasitology1999,37,1:1
7Which response criteria besthelp predict survival of patients with hepatocellular carcinomafollowing chemoembolization? A validation study of old and newmodels显示文摘Shim JH Lee HC Kim SO 2012Radiology2012,262,:1
8A new constrained weigh- ted least squares algorithm for TI)OA-based localization 显示文摘Lin L So HC Chan FKW 2013Signal Processing2013,93,11:1
9Detection of Boma disease virus p24 RNA in peripheral blood cells from Brazilian mood and psychotic disorder patients显示文摘Miranda HC Nunes SO Cairo ES 2006J Affect Disord2006,90,:1
10Nuclear and cytoplasmic accumula- tion of Ep-ICD is frequently detected in human epithelial cancers 显示文摘Ralhan R He HC So AK 2010PLoS One2010,5,14:1
11Modulation of the Ca (2+)- activated Cl (-) channel by 14-3-3 epsilon 显示文摘Chan HC Wu WL So SC 2000Biochem Biophys Res Commun2000,270,2:1
12Neuroprotective effects of Lycium barbarum Lynn on protecting retinal ganglion cells in an ocular hypertension model of glaucoma显示文摘Chan HC Chang RC Koon-Ching Ip A Chiu K Yuen WH Zee SY So KF 0,,01:1
13The risk of bladder cancer in Korean diabetic subjects treated with pioglitazone显示文摘Song SO Kim KJ Lee BW Kang ES Cha BS Lee HC 2012Diabetes Metab J2012,36,5:1
14Nuclear and cytoplasmicaccumulation of Ep-ICD is frequently detected in human epithelialcancers显示文摘Ralhan R He HC So AK 2010PLoS One2010,5,11:1
15Rates of referable eye disease in the Scottish National Diabetic Retinopathy Screening Programme显示文摘Looker HC Nyangoma SO Cromie JA 2014Br J Ophthalmol2014,98,:1
16Rates of referable eye disease in the Scottish National Diabetic Refinopathy Screening Programme显示文摘Looker HC Nyangoma SO Cromie DT 2014Br J Ophthalmol2014,98,6:1
17Evaluating the heritability ex-plained by known susceptibility variants: a survey of ten com-plex diseases显示文摘So HC Gui AH Chemy SS 2011Genet Epidemiol2011,35,5:1
18Detection of Borna disease virus p24 RNA in peripheral blood cells from Brazilian mood and psychotic disorder patients显示文摘Miranda HC Nunes SO Calvo ES 2006J Affect Disord2006,90,1:1
19Detection of Borna disease virus p24 RNA in peripheral blood cells from Brazilian mood and psychotic disorder patients显示文摘Miranda HC Nunes SO Calvo ES 2006J Affect Disord2006,90,1:1
20Time-delay estimation for sinusoidal signals显示文摘So HC 2001IEE Proceedings-Radar Sonar and Navigation2001,148,6:1
返回顶部 每页显示:
共2页 首页 上一页 第1页 下一页 末页 /2 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费